RANGER II SFA PIVOTAL TRIAL1
Prospective, Multi-Center, Randomized Controlled Trial Ranger Drug-Coated Balloon vs. Uncoated Balloon (3:1).
Follow-up through 5 years
Ranger demonstrated nearly 90% K-M primary patency at 12 months
Primary safety endpoint was freedom from MAE and primary effectiveness endpoint was binary primary patency.
|Primary Safety Endpoint
(Freedom from MAE)
|Primary Effectiveness Endpoint
(Binary Primary Patency)
2. Kaplan-Meier Estimate: Primary patency as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at the 12-month follow-up visit, in the absence of clinically-driven TLR or bypass of the target lesion.
* At risk denotes the number subjects entered in the calculation at the time interval.
** Log-rank p-value compares the entire K-M curves from time zero to full one year follow-up window.
Clinically Driven TLR (CD-TLR) & Mortality
Ranger demonstrated significantly lower CD-TLR and no difference in mortality vs. PTA at 12 months.
4. Log-rank p-value compares the entire K-M curves from time zero to full one year follow-up window.
Ranger PK Substudy5
- Designed to evaluate the levels of paclitaxel in the systemic circulation of 12 subjects who were treated with Ranger DCB
- Protocol required blood draws: Baseline, 10 minutes, 30 minutes, 1, 3, 6, 24 or 48 hours, 7 days and 30 days after last Ranger DCB treatment and removal
- The limit of quantification was defined as < 1 ng/mL
- Average number of DCBs used per patient: 1.75
5. RANGER II SFA PK Substudy presented by Ravish Sachar, MD. VIVA 2019.
Ranger is a registered or unregistered trademark of Boston Scientific Corporation or its affiliates. All other trademarks are the property of their respective owners.
Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.
Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.